High incidence of HER-2 positivity in inflammatory breast cancer.

[1]  S. Ménard,et al.  HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Espié,et al.  Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer , 2002, Oncogene.

[3]  Peter A Kaufman,et al.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.

[4]  E. Perez.  The role of adjuvant monoclonal antibody therapy for breast cancer: Rationale and new studies , 2001, Current oncology reports.

[5]  A. Thor.  Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? , 2001, Journal of the National Cancer Institute.

[6]  D. Hayes,et al.  When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[8]  M. Untch,et al.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Paik,et al.  HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. , 2000, Journal of the National Cancer Institute.

[10]  I. Ellis,et al.  Recommendations for HER2 testing in the UK , 2000, Journal of clinical pathology.

[11]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Ebbs,et al.  Multimodality therapy in inflammatory breast cancer: is there a place for surgery? , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  S. Merajver,et al.  Molecular biology of breast cancer metastasis: Inflammatory breast cancer: clinical syndrome and molecular determinants , 2000, Breast Cancer Research.

[14]  N. Sneige,et al.  HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. , 2000, American journal of clinical pathology.

[15]  E. Shpall,et al.  Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Vincent-Salomon,et al.  ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. , 2000, European journal of cancer.

[17]  A. Gown,et al.  HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. , 2000, American journal of clinical pathology.

[18]  S. Barsky,et al.  A novel human xenograft model of inflammatory breast cancer. , 1999, Cancer research.

[19]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Press,et al.  The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. , 1999, Seminars in oncology.

[21]  M. Dowsett,et al.  Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. , 1999, Cancer research.

[22]  J. Fletcher,et al.  HER-2/neu (c-erb-B2) gene and protein in breast cancer. , 1999, American journal of clinical pathology.

[23]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Vij,et al.  Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Canellos.  Clinical research saves money: reflections on high-dose therapy of breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D A Berry,et al.  erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.

[27]  C. Rose,et al.  Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2. , 1998, Anticancer research.

[28]  C. Shapiro,et al.  High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Ahomadégbé,et al.  Association of c‐erbB2‐gene amplification with poor prognosis in non‐inflammatory breast carcinomas but not in carcinomas of the inflammatory type , 1994, International journal of cancer.

[30]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[31]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[32]  B. Asselain,et al.  Prognostic factors in inflammatory breast cancer and therapeutic implications. , 1994, European journal of cancer.

[33]  Giampietro Gasparini,et al.  Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,” , 1993 .

[34]  W. McGuire,et al.  Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. , 1992, Annual review of medicine.

[35]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[37]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[38]  F. Rosato,et al.  Diseases of the Breast , 1972 .